Otitis Media News and Research

RSS
Acute otitis media (AOM) is a common childhood disease with important ramifications to the overall health of infants and young children. The peak incidence of AOM occurs at 6 to 18 months of age, but it can also occur in older children. Complications of AOM include persistent middle ear effusion, chronic otitis media, transient hearing loss, or speech delays.
Implanting tubes in ears is less likely to improve long-term cognitive and functional development

Implanting tubes in ears is less likely to improve long-term cognitive and functional development

Duration of common pediatric respiratory infections estimated

Duration of common pediatric respiratory infections estimated

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

Air pollution link to early childhood pneumonia

Air pollution link to early childhood pneumonia

Smartphone-enabled otoscope provides clear images of ear tympanic membrane

Smartphone-enabled otoscope provides clear images of ear tympanic membrane

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Short-term hearing loss during childhood may lead to persistent hearing deficits

Short-term hearing loss during childhood may lead to persistent hearing deficits

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Wellcome Trust-funded study could point to new therapies for glue ear

Wellcome Trust-funded study could point to new therapies for glue ear

Common sugar molecule promising target for development of broad-spectrum vaccine

Common sugar molecule promising target for development of broad-spectrum vaccine

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Interleukin-10 levels predict otitis media culprit

Interleukin-10 levels predict otitis media culprit

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Complications of suppurative otitis media characterized

Complications of suppurative otitis media characterized

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

Trauma, infection link with stroke seen in children

Trauma, infection link with stroke seen in children

Complications of suppurative otitis media characterized

Complications of suppurative otitis media characterized

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.